South Korea’s SK Inc., Develops Its CDMO Capabilities via Investment in the Center for Breakthrough Medicines
To come along with the clinical trials conducted by one of SK Inc.’s child companies, SK biopharmaceuticals, SK is taking a wider view of the future and investing in CMO infrastructure with CBM. This is already in the wake of the 2021 creation of SK Pharmateco and acquiring of AMPAC Fine Chemicals, SK biotek, SK biotech Ireland, and Yposkesi.
It's free! Log in now to read
LATEST
NUS Researchers Use Evolutionary Biology Models to Map Singapore Shophouse Architectural Development
2026-08-11
City St George’s Launches €6 Million REMADE Project to Advance Circular Renovation in Urban Neighborhoods
2026-08-10
Digital Science Releases Two Model Context Protocol Servers for Dimensions Research Platform
2026-08-10
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia




